Eli Lilly’s “weight loss medicine” Mounjaro is completely out of stock
- Japan Second Round of Nuclear Contaminated Water Discharge Set to Commence
- Johns Hopkins University: Early Plasma Therapy Reduces Long COVID Risk
- Ketogenic Diet Linked to Heart Diseases and Cancers
- TROP2 ADC for Breast Cancer Succeeded In Phase III Clinical Trials
- Lead Poisoning’s More Serious Impacts on Health and IQ
- Startling Link Between Alcohol and Alzheimer’s Disease
Eli Lilly’s “weight loss medicine” Mounjaro is completely out of stock
- Nearly 300 People Food Poisoning in Japanese 130-Year Restaurant
- FDA’s First Potential TIL Therapy Review Delayed: How to Understand FDA’s “Resource Constraints”?
- A Chinese Doctor Accused of Accepting Bribes Totaling US$166 Million
- Nuclear contaminated water: Japanese government paid bribes and corrected the IAEA report
- Top 20 Companies of Instruments and Medical Equipment In The World
- The first DMD gene therapy SRP-9001 may cost 4 million US dollars
- How long can the patient live after heart stent surgery?
The demand is too exaggerated: Eli Lilly’s “weight loss medicine” Mounjaro is completely out of stock.
Eli Lilly’s diabetes treatment drug Mounjaro was found to be able to make patients lose up to 23kg in weight.
Although the drug is not officially approved by the US FDA for weight loss, the news triggered a panic buying frenzy and is currently out of stock.
Following Novo Nordisk’s weight-loss drug sameglutide, another major pharmaceutical company Eli Lilly’s weight-loss drug Mounjaro is also out of stock.
Weight-lossers have snapped up the drugs, leaving many diabetics without them.
As early as last month, the U.S. Food and Drug Administration (FDA) said three high-dose versions of Mounjaro were “intermittently out of stock” throughout July due to increased demand.
Recently, the FDA has updated the out-of-stock list, added a fourth dose, and extended the shortage of one of the high-dose versions to September. Currently, there are only two low-dose versions of Mounjaro available to consumers.
On Wednesday, July 25, an Eli Lilly spokesperson confirmed that Mounjaro is indeed facing a comprehensive shortage and that the company is working hard to invest in expanding production capacity.
Mounjaro, also known as tirzepatide, was approved in the United States last year to help people with type 2 diabetes manage blood sugar levels.
But in trials, Lilly found that higher doses of Mounjaro caused patients to lose as much as 23kg. Lilly is currently awaiting FDA approval, making Mounjaro an official obesity treatment.
However, even before the approval, the drug has already been bought by consumers who want to lose weight.
Previously, the pharmaceutical company Novo Nordisk reported that its weight-loss drugs sameglutide weight-loss version (Wegovy) and diabetes version (Ozempic) are facing shortages, and true diabetic patients can only return one day from the original one injection per week.
Last week, the shortage even spread to the previous generation of GLP-1 product liraglutide (Saxenda). The drugs that diabetics depend on for a living were sold out by people who lost weight and fell into a situation of “no drug available”.
According to a research report by Morgan Stanley, by 2030, the global weight-loss drug market may reach 77 billion US dollars, which is more than 20 billion US dollars higher than the bank’s original forecast.
Analysts also expect that Novo Nordisk and Eli Lilly will maintain their leading positions in the field even if competition intensifies, and the two pharmaceutical companies will occupy an 82% share of the weight-loss drug market for a long time.
Eli Lilly’s “weight loss medicine” Mounjaro is completely out of stock
(source:internet, reference only)
Disclaimer of medicaltrend.org
